Non-Proliferative Diabetic Retinopathy Clinical Trial
Official title:
Faricimab for Retinal Non-Perfusion Associated With Non-Proliferative Diabetic Retinopathy: The MAGIC Phase 2, Multi-Center, Open-Label, Randomized Controlled Trial
The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.
Group 1: Subjects will be administered intravitreal faricimab every 4 through week 48 and then will be receive faricimab every 16 weeks with an end of study visit at week 96. At any visit after Week 48, if rescue criteria are met, faricimab 6mg will be given every 4 weeks and the subject will continue dosing through the end of the trial. Group 2: Subjects are seen and observed every 16 weeks. Starting at Week 48, subjects will be administered intravitreal faricimab every 4 weeks from week 48 to week 92 with an end of study visit at week 96. At any visit before Week 48, if rescue criteria are met, faricimab will be given every 4 weeks and the subject will continue dosing through the end of the trial. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04511715 -
Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT02388984 -
Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy
|
Phase 3 | |
| Completed |
NCT01646047 -
Diabetes Visual Function Supplement Study
|
N/A | |
| Not yet recruiting |
NCT01107132 -
Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus
|
N/A | |
| Recruiting |
NCT06270836 -
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
|
Phase 3 | |
| Completed |
NCT01872611 -
Nepafenac Once Daily for Macular Edema - Study 2
|
Phase 3 | |
| Completed |
NCT01853072 -
Nepafenac Once Daily for Macular Edema - Study 1
|
Phase 3 | |
| Completed |
NCT02096874 -
Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema
|
Phase 4 | |
| Not yet recruiting |
NCT04000789 -
The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR)
|
N/A | |
| Active, not recruiting |
NCT05695417 -
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
|
Phase 1 | |
| Recruiting |
NCT05222633 -
Anti-VEGF in Real-world
|
||
| Completed |
NCT02062034 -
Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy
|
Phase 2 | |
| Completed |
NCT02435862 -
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
|
Phase 2 | |
| Terminated |
NCT05066230 -
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
|
Phase 3 | |
| Recruiting |
NCT05393284 -
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
|
Phase 2 | |
| Completed |
NCT01571232 -
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
|
Phase 2 |